Table 5.

Overview of in vivo studies related to EGCG.

Polyphenol	Animal Model	Dose/ Duration	Anti-Tumor Effects	Type IV Collagenase-Mediated Mechanisms	Reference
EGCG [(2 R,3 R)-3′,4′,5,5′,7-pentahydroxyflavan-3-yl 3,4,5-trihydroxybenzoate]	Balb/c nu/nu mice injected with SCC-9	10, 20 mg/kg daily through oral gavage for 45 days	↓tumor weight ↓tumor volume	not specified	[62]
	Balb/c nude mice injected with CL1-5	50 mg/kg intraperitoneally twice a week for 6 weeks	↓metastatic incidence in lungs	not specified	[60]
	Balb/c nu/nu mice injected with PANC-1	60, 80, 100 mg/kg daily by gavage, 5 days a week for 28 days	↓angiogenesis ↑apoptosis ratio ↓pancreas weight	↓MMP-2 mRNA ↓pAkt protein ↓pPI3 K protein ↓pERK protein	[63]
	SCID mice injected with NA (EBV-positive)	30 mg/kg every day or 50 mg/kg every two days, by oral gavage for 8 weeks	↓tumor volume	not specified	[61]
	Balb/c mice injected with HuCC-T1	20 mg/kg once subcutaneously beside tumor when it reached 4–5 mm in diameter	↓tumor volume	↓MMP-2, -9 protein	[56]
	Balb/c mice injected with SW780	25, 50, 100 mg/kg daily intraperitoneally for 3 weeks	↓tumor weight ↓tumor volume	↓MMP-9 mRNA, protein ↓pNF-κB p65 protein ↓NF-κB mRNA	[57]
	Balb/c athymic nude mice injected with A549	20 mg/kg with or without 10 mg/kg BAY11-7082, intraperitoneally for 21 days	↓tumor weight ↓tumor volume	↓pNF-κB protein	[59]
	Balb/c athymic nude mice injected with patient-derived lung cancer samples	10 mg/kg (free EGCG) or 5 mg/kg (PLGA-encapsulated EGCG) daily intraperitoneally for a month	↓tumor weight ↓tumor volume	↓pNF-κB protein	[58]

Legend: ↑ activation or increase; ↓ inhibition or decrease.